Inhibition of Neuropilin 1 (NRP1), which is expressed in pancreatic tissue, has been reported to improve glucose tolerance in type 2 diabetes as well as in glucose intolerance after SARS-CoV2 infection [7,8,9]. Here, NRP1 is linked to Glucose intolerance.